BML Capital Management’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

BML Capital Management’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,440,000	Closed	-$4.5M	–	35
2023 Q1	$4.5M	Hold	6,440,000	–	–	3.89%	11
2022 Q4	$5.8M	Buy	+6,440,000	New	+$18.7M	5.54%	8

BML Capital Management's STSA Position: Q2 2023 in Review

BML Capital Management sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q2 2023, closing a stake of 6,440,000 shares — an estimated $4.5M sold.

BML Capital Management first reported a position in STSA in Q4 2022 and held it in 2 quarters. The position peaked at $5.8M in Q4 2022. 0 funds tracked by Wall St. Rank hold STSA as of Q2 2023.

BML Capital Management reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
BML Capital Management sold 6,440,000 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $4.5M.
BML Capital Management first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
BML Capital Management's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $5.8M in Q4 2022.
0 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on BML Capital Management's 13F filing for Q2 2023, filed 24 Jul 2023.